Every life sciences transaction brings years of scientific, clinical, and regulatory work into diligence. Whether the transaction involves licensing or partnering an individual program, selling an asset, or acquiring an entire company and its portfolio, the underlying science is ultimately disclosed. A counterparty cannot evaluate what it cannot see.
That creates a tension inherent to every transaction: meaningful diligence requires opening the underlying evidence, but every disclosure creates exposure.
Any platform or technology operating in this category should expect scrutiny, and the questions arrive in a predictable order. What will you do with my data? What will you permit the other side to do with it? Where and how will it be stored? And if circumstances change, can I withdraw? These are the right questions, and they deserve unambiguous answers.
So before describing what our platform does, we will be explicit about what it will never do. Each commitment below is enforced by the architecture rather than by policy alone, which is what allows it to hold under scrutiny and in its absence.
Five things we don’t do
1. We don’t allow your competitors to use your data.
The insights generated from your data remain within your engagement; they do not surface in a competitor’s analysis, and they do not sharpen anyone’s position at your expense.
2. We don’t let your data leak into anyone else’s environment.
Your confidential material is protected and only available to you and the parties you authorize; vacuum-sealed, in effect. Nothing crosses between customer environments: no shared learning, no shared retrieval, no output informed by another company’s work.
The exposure at stake extends beyond the documents themselves. The pattern of your activity (which partners you are approaching, how the asset or company is being positioned, where you believe it fits) can be as commercially revealing as the underlying data. In a market where participants watch one another closely, evidence that a particular asset or company is being shopped is actionable intelligence in the wrong hands. That analysis never leaves your instance.
3. We don’t allow secondary distribution.
Material you bring into Prudentia is not extracted, forwarded, or repurposed beyond the use you authorized. Your files do not become a dataset to be resold, mined, or quietly put to secondary use; no copy leaves the environment to serve another purpose.
4. We don’t override your permissions.
The access controls you define are the controls we enforce. Your project owner controls permissions and groups: who may see what, where, and for how long. View-only remains view-only. We mirror your controls; we never relax them.
Where your confidential material resides in a virtual data room, the VDR remains the authoritative source. We maintain integrations with established VDR providers, and when you connect a data room you designate precisely which folders are shared; nothing beyond that designation is visible. Assessment proceeds against that material under the access rules you already govern.
5. We don’t hold your data hostage.
Access, once granted, remains revocable. Every connection carries a defined end date, and the platform enforces it: if the agreement provides that access ends on July 31, access ends on July 31, without depending on anyone’s memory. A connections view displays every active connection, its counterparty, and its viewing activity; you may terminate any of them yourself, at any time.
The terms of disclosure remain yours throughout. You define the window when you share, you observe the connection while it is open, and you close it at your discretion; a counterparty’s visibility ends when you end it.
What we do with your data, and why
The platform makes your data more effective within the boundaries you define, and every capability that follows depends on the commitments above holding.
For example, a pharma business development organization or an investor may be carrying 20 to 50 active projects at any given time. Your company competes for the attention of evaluators whose time is already committed, and the data room often compounds the difficulty: hundreds of thousands of documents, at times millions, organized by accretion rather than design. Everything we do with your data serves a single purpose: moving the other side to their diligence questions quickly, while the discussion retains momentum. From your side of the table, each capability below should read as progress toward a decision.
We keep your VDR authoritative
Your virtual data room remains the authoritative source. Assessment runs against your confidential material under permissions you already govern, so custody of the data never transfers.
We organize it before we assess it
As documents enter the system, each is read and classified to its domain: clinical, regulatory, intellectual property, commercial, and the remaining categories of a diligence review. A data room that accumulated four hundred folders across years of programs, audits, and prior processes resolves into a consistent, navigable structure, and reviewers working within a domain touch only the documents that belong to it.
We assess it, with experts in the loop
Your science and company deserves to be evaluated quickly and fairly. The platform conducts structured scientific and technical diligence using assessment frameworks matched to therapeutic area, indication, and modality. It interrogates the underlying evidence, generates findings, and surfaces the relevant support for expert review. Every finding is footnoted to its source; opening the footnote retrieves the underlying document with the relevant passage highlighted, whether it appears on page 3 or page 190 of 347.
Diligence teams can interrogate, refine, or adjust findings based on their expertise and judgment, with written rationale and a complete change log retained. The result is AI-driven diligence with experts in the loop: the platform does the intensive work of analyzing and synthesizing the evidence, while the experts evaluating the opportunity apply the judgment that ultimately informs the transaction decision.
We contain it
Your data is protected: encrypted in transit and at rest and governed by role-based access. This is the security-by-design architecture the rest of the platform assumes.
We make it inspectable
The controls are built to withstand examination. Where your security and compliance functions conduct a formal assessment, the architecture is designed to be audited; where no dedicated security function exists, the same isolation applies without one. The protection does not vary with the size of the team verifying it.
The payoff. For an innovator, biotech or pharma, the case for engaging is direct: this is how your science moves toward a transaction, and toward the partner you actually want across the table, faster. Diligence that once consumed months of disconnected effort compresses toward hours, and every control you began with remains in force. Ultimately, we get you to the deal table faster.
Built on trust, by design
You should not have to choose between the platform you would trust with your science and the one capable of positioning your company. The refusals above are what make the intelligence safe and trusted. You retain every control you began with, and come away with a clearer path to a transaction and partnership.
See how it works: Your Data, Your Control →
